Sobi’s Orfadin® (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee
OAKVILLE, Ontario--(BUSINESS WIRE)--Sobi’s Orfadin (nitisinone) received a positive reimbursement recommendation for the treatment of HT-1 from the CADTH Canadian Drug Expert Committee.